What is tibolone - And is it a SPEAR?

Climacteric

Volumn 5, Issue 3, 2002, Pages 236-239

  Purdie, D W ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Function; Structure; Tibolone

Indexed keywords

ANDROGEN; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE;

CARDIOVASCULAR SYSTEM; DRUG STRUCTURE; ESTROGEN RESPONSIVE ELEMENT; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0036387535     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.3.236.239     Document Type: Review

References (25)

1. Visser De J, Coert A, Feenstra H, et al. Endocrinological studies with (7α, 17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD14). Arzneim Forsch/Drug Res 1984;34:1010-17
2. Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990;35:535-41
3. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8
4. Gruber CJ, Tschuggel W, Schneeberger C, et al. Production and action of estrogens. N Engl J Med 2002;346:340-52
5. Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol 1993;7:4-11
6. Delmas P, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;237:1641-7
7. Purdie DW, Steel SA, Howey S, et al. The technical and logistical feasibility of population densitometry using DXA and directed HRT intervention: a 2-year prospective study. Osteoporosis Int 1996;3:S31-6
8. Pasqualini JR, Kloosterboer HJ. Estrogen sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer. Inhibitory effect by tibolone and its metabolites. Acta Obstet Gynaecol Scand 1997;76:35
9. Compel A, Kandouz M, Siromachkova M, et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997;1:77-9
10. Chetrite GS, Kloosterboer HJ, Philippe JC, et al. Effects of Org OD14 (Livial®) and its metabolites in 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anticancer Res 1999;19:261-8
11. Ginsburg J, Prelevic G, Butler D, et al. Clinical experience with tibolone over 8 years. Maturitas 1995;21:71-6
12. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with ribolone, estriol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101-7
13. Rymer JM. The effects of tibolone. Gynecol Endocrinol 1998;12:213-20
14. Hammar M, Christau S, Nathorst-Böös J, et al. A double-blind, randomized study comparing the effects of Livial and Kliogest in postmenopausal women with climacteric complaints. Acta Obstet Gynaecol Scand 1996;75:52-3
15. Ederveen AGH, Kloosterboer HJ. Tibolone exerts an estrogenic effect on bone leading to prevention of bone loss and reduction in bone resorption in ovariectomized rats. Osteoporosis Int 1999;8:95
16. Laan E, Van Lunsen RH, Everaerd W. Effect of tibolone on vaginal blood flow and sexual desire in postmenopausal women. Climacteric 2001;4:28-41
17. Dören M, Rübig HJ, Holzgreve W. Resistance of pelvic arteries and plasma lipids in postmenopausal women: comparative study of tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Am J Obstet Gynecol 2000;183:575-82
18. Bjarnson N, Bjarnson KH, Bennink HJ, et al. Tibolone influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
19. Walker I, Davidson A, Yates R, McEwan HP. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 1985;53:303-5
20. Bedenek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas 1987; (Suppl 1):25-33
21. Lloyd G, McGing A, Patel N, et al. A randomized placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000;14:99-104
22. Genazzani A, Benedek-Jaszmann DM, Andolsek L, et al. Org OD 14 and the endometrium. Maturitas 1991;13:243-51
23. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503
24. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas 1987;(Suppl 1);67-72
25. Parkin D, Smith F, Al-Azzawi F, et al. Effects of long-term Org OD14 administration on blood coagulation in climacteric women. Maturitas 1997;9:95-101